Protein filter therapy for dilated cardiomyopathy
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a protein filtering treatment (immunoadsorption) for people with dilated cardiomyopathy who have a specific antibody linked to heart damage. It aims to see if removing these antibodies can improve heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with dilated cardiomyopathy
- Has a specific antibody (anti-β1-adrenergic receptor) in your blood
- Between 18 and 75 years old
- Heart's pumping ability (LVEF) is 40% or less
- Heart failure symptoms (like shortness of breath or fatigue) for at least 6 months
- On stable heart failure medications for at least 1 month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
This trial tests a new treatment called FAP iCDC for people with end-stage dilated cardiomyopathy, a type of heart muscle disease. It aims to see if this therapy is safe and helps improve heart function when standard medicines are no longer enough.
This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.
This study aims to find and treat rare types of heart muscle disease early. If you have heart failure but no known heart disease, researchers will use MRI and other tests to see if a rare cause is behind your symptoms and then offer targeted treatment.
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
Hear when a new Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.